{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:56:49Z","timestamp":1773867409065,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Farmac\u00e9utica Espa\u00f1a S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41669-025-00633-8","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:51:10Z","timestamp":1768319470000},"page":"381-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0509-8717","authenticated-orcid":false,"given":"Sof\u00eda","family":"de Pedro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-0619","authenticated-orcid":false,"given":"Mar\u00eda","family":"Presa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-7486","authenticated-orcid":false,"given":"Josep","family":"Gamez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"G\u00f3mez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90:981\u20137. https:\/\/doi.org\/10.1136\/jnnp-2019-320314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"633_CR2","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L, Crabtree M, Herepath M, Priedane E, Viejo Viejo I, Agush S, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268:3706\u201316. https:\/\/doi.org\/10.1007\/s00415-020-09998-8.","journal-title":"J Neurol"},{"key":"633_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000494291","volume":"52","author":"MC Broers","year":"2019","unstructured":"Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52:161\u201372. https:\/\/doi.org\/10.1159\/000494291.","journal-title":"Neuroepidemiology"},{"key":"633_CR4","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van Den Bergh","year":"2021","unstructured":"Van Den Bergh PYK, Van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision. Eur J Neurol. 2021;28:3556\u201383. https:\/\/doi.org\/10.1111\/ene.14959.","journal-title":"Eur J Neurol"},{"key":"633_CR5","doi-asserted-by":"publisher","first-page":"6961","DOI":"10.3390\/jcm12226961","volume":"12","author":"D Cocito","year":"2023","unstructured":"Cocito D, Peci E, Torrieri MC, Clerico M. Subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: a historical perspective. JCM. 2023;12:6961. https:\/\/doi.org\/10.3390\/jcm12226961.","journal-title":"JCM"},{"key":"633_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116497","volume":"408","author":"JA Allen","year":"2020","unstructured":"Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? J Neurol Sci. 2020;408:116497. https:\/\/doi.org\/10.1016\/j.jns.2019.116497.","journal-title":"J Neurol Sci"},{"key":"633_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130:951-957.e11. https:\/\/doi.org\/10.1016\/j.jaci.2012.06.021.","journal-title":"J Allergy Clin Immunol"},{"key":"633_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/cei.12694","volume":"182","author":"M Ponsford","year":"2015","unstructured":"Ponsford M, Carne E, Kingdon C, Joyce C, Price C, Williams C, et al. Facilitated subcutaneous immunoglobulin (fSCIg) therapy \u2013 practical considerations. Clin Exp Immunol. 2015;182:302\u201313. https:\/\/doi.org\/10.1111\/cei.12694.","journal-title":"Clin Exp Immunol"},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/jns.12573","volume":"28","author":"V Bril","year":"2023","unstructured":"Bril V, Hadden RDM, Brannagan TH, Bar M, Chroni E, Rejdak K, et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst. 2023;28:436\u201349. https:\/\/doi.org\/10.1111\/jns.12573.","journal-title":"J Peripher Nerv Syst"},{"key":"633_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fimmu.2020.00981","volume":"11","author":"E Wiesik-Szewczyk","year":"2020","unstructured":"Wiesik-Szewczyk E, So\u0142dacki D, Paczek L, Jahnz-R\u00f3\u017cyk K. Facilitated subcutaneous immunoglobulin replacement therapy in clinical practice: a two center, long-term retrospective observation in adults with primary immunodeficiencies. Front Immunol. 2020;11:981. https:\/\/doi.org\/10.3389\/fimmu.2020.00981.","journal-title":"Front Immunol"},{"key":"633_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/1750743X.2024.2354091","volume":"16","author":"PM Ellerbroek","year":"2024","unstructured":"Ellerbroek PM, Hanitsch LG, Witte T, Lougaris V, Hagen PMV, Paassen PV, et al. Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study. Immunotherapy. 2024;16:679\u201391. https:\/\/doi.org\/10.1080\/1750743X.2024.2354091.","journal-title":"Immunotherapy"},{"key":"633_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14737167.2022.2000862","volume":"22","author":"J Darb\u00e0","year":"2022","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Chronic inflammatory demyelinating polyneuropathy in Spain: a retrospective analysis of hospital incidence and medical costs. Expert Rev Pharmacoecon Outcomes Res. 2022;22:665\u201370. https:\/\/doi.org\/10.1080\/14737167.2022.2000862.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"633_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mus.26315","volume":"58","author":"D Mengel","year":"2018","unstructured":"Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, et al. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Muscle Nerve. 2018;58:681\u20137. https:\/\/doi.org\/10.1002\/mus.26315.","journal-title":"Muscle Nerve"},{"key":"633_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ene.12245","volume":"21","author":"M Mahdi-Rogers","year":"2014","unstructured":"Mahdi-Rogers M, McCrone P, Hughes RAC. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21:34\u20139. https:\/\/doi.org\/10.1111\/ene.12245.","journal-title":"Eur J Neurol"},{"key":"633_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110532","volume":"9","author":"R Alexandrescu","year":"2014","unstructured":"Alexandrescu R, Siegert RJ, Turner-Stokes L. Functional outcomes and efficiency of rehabilitation in a national cohort of patients with Guillain\u2013Barr\u00e9 syndrome and other inflammatory polyneuropathies. PLoS ONE. 2014;9:e110532. https:\/\/doi.org\/10.1371\/journal.pone.0110532.","journal-title":"PLoS ONE"},{"key":"633_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206205","volume":"13","author":"V Divino","year":"2018","unstructured":"Divino V, Mallick R, DeKoven M, Krishnarajah G. The economic burden of CIDP in the United States: a case\u2013control study. PLoS ONE. 2018;13:e0206205. https:\/\/doi.org\/10.1371\/journal.pone.0206205.","journal-title":"PLoS ONE"},{"key":"633_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mus.24109","volume":"50","author":"JT Guptill","year":"2014","unstructured":"Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, Krueger A, et al. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014;50:47\u201351. https:\/\/doi.org\/10.1002\/mus.24109.","journal-title":"Muscle Nerve"},{"key":"633_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.923","volume":"8","author":"G Le Masson","year":"2018","unstructured":"Le Masson G, Sol\u00e9 G, Desnuelle C, Delmont E, Gauthier\u2010Darnis M, Puget S, et al. Home versus hospital immunoglobulin treatment for autoimmune neuropathies: a cost minimization analysis. Brain Behav. 2018;8:e00923. https:\/\/doi.org\/10.1002\/brb3.923.","journal-title":"Brain Behav"},{"key":"633_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/ene.13841","volume":"26","author":"C Rosier","year":"2019","unstructured":"Rosier C, Graveline N, Lacour A, Antoine J-C, Camdessanch\u00e9 J-P. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines? Eur J Neurol. 2019;26:575\u201380. https:\/\/doi.org\/10.1111\/ene.13841.","journal-title":"Eur J Neurol"},{"key":"633_CR20","unstructured":"Fern\u00e1ndez C, Lorenzo H, Vrotsou K, Aresti U, Rica I, S\u00e1nchez E. Estudio De Crecimiento De Bilbao. Curvas y tablas de crecimiento (Estudio Transversal) [Internet]. 2011. http:\/\/www.fundacionorbegozo.com\/wp-content\/uploads\/pdf\/estudios_2011.pdf."},{"key":"633_CR21","unstructured":"Ortega Eslava A, Mar\u00edn Gil R, Fraga Fuentes MD. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario."},{"key":"633_CR22","unstructured":"Instituto Nacional de Estad\u00edstica. \u00cdndice de Precios al Consumo (IPC) [Internet]. 2025 [cited 2025 Nov 5]. https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176802&menu=ultiDatos&idp=1254735976607. Accessed 5 Nov 2025."},{"key":"633_CR23","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha T\u00e9cnica Plangamma [Internet]. 2024. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/78149\/FichaTecnica_78149.html..pdf."},{"key":"633_CR24","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha t\u00e9cica Privigen [Internet]. 2024. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/08446004\/FT_08446004.html.pdf."},{"key":"633_CR25","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha T\u00e9cnica Hizentra [Internet]. 2024. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/11687006\/FT_11687006.html.pdf."},{"key":"633_CR26","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. BOTPLUS [Internet]. 2022. https:\/\/botplusweb.farmaceuticos.com\/."},{"key":"633_CR27","unstructured":"Distribuci\u00f3n de la poblaci\u00f3n y accesibilidad a los servicios en Espa\u00f1a. Madrid, Valencia: Fundaci\u00f3n Ram\u00f3n Areces\u202f; IVIE, Instituto Valenciano de Investigaciones Econ\u00f3micas; 2021."},{"key":"633_CR28","unstructured":"motor.es. Cu\u00e1nto consume un coche, buscar por marca y modelo Calcula tu gasto medio de combustible en nuestra calculadora [Internet]. 2024. https:\/\/www.motor.es\/energia\/calculadora-coste-km."},{"key":"633_CR29","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Tasas de actividad por distintos grupos de edad, sexo y comunidad aut\u00f3noma [Internet]. 2024. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=4206."},{"key":"633_CR30","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Coste laboral por hora efectiva, comunidad aut\u00f3noma, sectores de actividad [Internet]. 2024. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=6062."},{"issue":"Suppl 1","key":"633_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cei.12546","volume":"178","author":"A \u0160ediv\u00e1","year":"2014","unstructured":"\u0160ediv\u00e1 A, Chapel H, Gardulf A, European Immunoglobulin Map Group (35 European Countries) for European Society for Immunodeficiencies (ESID) Primary Immunodeficiencies Care in Development Working Party. Europe immunoglobulin map. Clin Exp Immunol. 2014;178(Suppl 1):141\u20133. https:\/\/doi.org\/10.1111\/cei.12546.","journal-title":"Clin Exp Immunol"},{"key":"633_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s10072-014-1632-9","volume":"35","author":"C Lazzaro","year":"2014","unstructured":"Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci. 2014;35:1023\u201334. https:\/\/doi.org\/10.1007\/s10072-014-1632-9.","journal-title":"Neurol Sci"},{"key":"633_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242630","volume":"15","author":"C Perraudin","year":"2020","unstructured":"Perraudin C, Bourdin A, Vicino A, Kuntzer T, Bugnon O, Berger J. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: a Swiss cost-minimization analysis. PLoS ONE. 2020;15:e0242630. https:\/\/doi.org\/10.1371\/journal.pone.0242630.","journal-title":"PLoS ONE"},{"key":"633_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s41669-023-00386-2","volume":"7","author":"R Mallick","year":"2023","unstructured":"Mallick R, Carlton R, Van Stiphout J. A budget impact model of maintenance treatment of chronic inflammatory demyelinating polyneuropathy with IgPro20 (Hizentra) relative to intravenous immunoglobulin in the United States. Pharmacoecon Open. 2023;7:243\u201355. https:\/\/doi.org\/10.1007\/s41669-023-00386-2.","journal-title":"Pharmacoecon Open"},{"key":"633_CR35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10198-021-01378-x","volume":"23","author":"L Alsina","year":"2022","unstructured":"Alsina L, Montoro JB, Moral PM, Neth O, Pica MO, S\u00e1nchez-Ram\u00f3n S, et al. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. Eur J Health Econ. 2022;23:551\u20138. https:\/\/doi.org\/10.1007\/s10198-021-01378-x.","journal-title":"Eur J Health Econ"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00633-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:46:01Z","timestamp":1773841561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00633-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00633-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.d.P. and M.P.G. are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consultant company specialized in the evaluation and assessment of healthcare interventions, which has received financial support from Takeda to develop the project. J.G. and F.J.G.D. declare no conflicts of interest. L.Q. received research grants from Instituto de Salud Carlos III \u2013 Ministry of Economy and Innovation (Spain), CIBERER, Fundaci\u00f3 La Marat\u00f3, GBS-CIDP Foundation International, and ArgenX. L.Q. received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi-Genzyme, Merck, Annexon, Alnylam, ArgenX, Dianthus, LFB, Avilar Therapeutics, Lycia Therapeutics, Nuvig Therapeutics, Takeda, and Roche. L.Q. serves on the Clinical Trial Steering Committees for Sanofi Genzyme, ArgenX, and Takeda and is principal investigator for UCB\u2019s CIDP01 trial and Sanofi\u2019s Mobilize and Vitalize trials. All authors declare they have not received financial support for drafting or reviewing the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data supporting the findings of this study are available within the paper and its Supplementary Information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable. Ethical approval is considered unnecessary according to national regulations, as this is not a study but a literature review, and nonpatient level data are managed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The economic model used in this study is not publicly available to protect commercial-in-confidence information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"S.d.P. and M.P.G. conceived the analysis, designed and programmed the decision analytical model. and drafted a results report. J.G., F.J.G., and L.Q. provided information about management of patients with CIDP in clinical practice. All authors reviewed the results report and participated in the data analysis and data interpretation. All authors had full access to the data and approved the final version of the manuscript for submission. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}